662 related articles for article (PubMed ID: 29133133)
1. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
2. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
3. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L; Di Santo J; Olive D
Front Immunol; 2020; 11():1132. PubMed ID: 32612604
[No Abstract] [Full Text] [Related]
5. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
[TBL] [Abstract][Full Text] [Related]
6. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
7. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
8. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
9. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
12. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.
Tarazona R; Sanchez-Correa B; Casas-Avilés I; Campos C; Pera A; Morgado S; López-Sejas N; Hassouneh F; Bergua JM; Arcos MJ; Bañas H; Casado JG; Durán E; Labella F; Solana R
Cancer Immunol Immunother; 2017 Feb; 66(2):233-245. PubMed ID: 27530271
[TBL] [Abstract][Full Text] [Related]
13. NK cell-based cancer immunotherapy: from basic biology to clinical application.
Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
15. New directions in natural killer cell-based immunotherapy of human cancer.
Farag SS; Fehniger TA; Becknell B; Blaser BW; Caligiuri MA
Expert Opin Biol Ther; 2003 Apr; 3(2):237-50. PubMed ID: 12662139
[TBL] [Abstract][Full Text] [Related]
16. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
17. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
[TBL] [Abstract][Full Text] [Related]
18. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.
Murray S; Lundqvist A
Hum Vaccin Immunother; 2016 Mar; 12(3):607-11. PubMed ID: 26402368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]